{"id":742107,"date":"2011-07-20T06:00:00","date_gmt":"2011-07-20T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/"},"modified":"2026-08-10T13:01:17","modified_gmt":"2026-08-10T17:01:17","slug":"merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/","title":{"rendered":"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        announced today that it has signed a new non-exclusive agreement with        Roche (SIX: RO, ROG; OTCQX: RHHBY), through the companies&#8217; respective        subsidiaries, for the global promotion, upon appropriate marketing        approvals, of VICTRELIS\u2122 (boceprevir) as part of a triple combination        therapy regimen with peginterferon alfa and ribavirin (peg\/riba).     <\/p>\n<p>       &#8220;Reaching physicians with important information about the use of        VICTRELIS in combination with peg\/riba is essential as we enter this new        era in the field of chronic hepatitis C,&#8221; said Adam H. Schechter,        executive vice president and president, Global Human Health, Merck.        &#8220;We&#8217;re pleased to work with Roche to help physicians help patients with        chronic hepatitis C around the world.&#8221;     <\/p>\n<p>       Under the terms of the agreement, Roche and Merck will work together in        global markets, including Europe, Asia and Latin America, to educate        physicians and patients about hepatitis C virus (HCV). The companies        previously announced an agreement to promote VICTRELIS in the United        States and collaborate to explore new treatment regimens for patients        with chronic HCV.     <\/p>\n<p>       &#8220;Improving treatment outcomes for more patients with chronic hepatitis C        is our ultimate goal,&#8221; said Pascal Soriot, Roche Pharmaceuticals        Division, chief operating officer. &#8220;Through this extended collaboration        and the education of health care professionals, Roche and Merck aim to        ensure that appropriate patients can benefit from triple combination        therapy.&#8221;     <\/p>\n<p>       <b>VICTRELIS in the United States<\/b>     <\/p>\n<p>       In the United States, VICTRELIS is approved for the treatment of chronic        hepatitis C genotype 1 infection, in combination with peginterferon alfa        and ribavirin, in adult patients (18 years of age and older) with        compensated liver disease, including cirrhosis, who are previously        untreated or who have failed previous interferon and ribavirin therapy.        The following points should be considered when initiating VICTRELIS for        treatment of chronic hepatitis C infection:     <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">         VICTRELIS must not be used as monotherapy and should only be used in          combination with peginterferon alfa and ribavirin.       <\/li>\n<li class=\"bwlistitemmargb\">         VICTRELIS efficacy has not been studied in patients who have          previously failed therapy with a treatment regimen that includes          VICTRELIS or other HCV NS3\/4A protease inhibitors.       <\/li>\n<li class=\"bwlistitemmargb\">         VICTRELIS in combination with peginterferon alfa and ribavirin has not          been studied in patients documented to be historical null responders          (less than a 2 log<sub> <\/sub>HCV-RNA decline by treatment week 12)          during prior therapy with peginterferon alfa and ribavirin. The          clinical studies included patients who were poorly interferon          responsive. Patients with less than 0.5 log<sub> <\/sub>HCV-RNA decline          in viral load at treatment week 4 with peginterferon alfa plus          ribavirin alone are predicted to have a null response (less than a 2          log HCV-RNA decline by treatment week 12) to peginterferon alfa and          ribavirin therapy.       <\/li>\n<\/ul>\n<p>       Poorly interferon responsive patients who were treated with VICTRELIS in        combination with peginterferon alfa and ribavirin have a lower        likelihood of achieving a sustained virologic response (SVR)<sup>1<\/sup>        , and a higher rate of detection of resistance-associated substitutions        upon treatment failure, compared to patients with a greater response to        peginterferon alfa and ribavirin.     <\/p>\n<p>       VICTRELIS was approved by the U.S. Food and Drug Administration on May        13 and is available to all U.S. pharmacies nationwide, including        specialty pharmacies.     <\/p>\n<p>       On July 18, Merck announced that the European Commission (EC) approved        VICTRELIS for the treatment of chronic hepatitis C genotype 1 infection,        in combination with peginterferon alfa and ribavirin, in adult patients        with compensated liver disease who are previously untreated or who have        failed previous therapy.     <\/p>\n<p>       <b>Important U.S. safety information about VICTRELIS<\/b>     <\/p>\n<p>       All contraindications to peginterferon alfa and ribavirin also apply        since VICTRELIS must be administered with peginterferon alfa and        ribavirin. Because ribavirin may cause birth defects and fetal death,        VICTRELIS in combination with peginterferon alfa and ribavirin is        contraindicated in pregnant women and in men whose female partners are        pregnant. Avoid pregnancy in female patients and female partners of male        patients. Patients must have a negative pregnancy test prior to therapy;        have monthly pregnancy tests; and use two or more forms of effective        contraception, including intrauterine devices and barrier methods,        during treatment and for at least six months after treatment has        concluded. Systemic hormonal contraceptives may not be as effective in        women while taking VICTRELIS. VICTRELIS is contraindicated in        coadministration with drugs that are highly dependent on CYP3A4\/5 for        clearance, and for which elevated plasma concentrations are associated        with serious and\/or life-threatening events. VICTRELIS also is        contraindicated in coadministration with potent CYP3A4\/5 inducers where        significantly reduced boceprevir plasma concentrations may be associated        with reduced efficacy. Drugs that are contraindicated with VICTRELIS        include: alfuzosin, carbamazepine, phenobarbital, phenytoin, rifampin,        dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride,        St. John&#8217;s Wort (hypericum perforatum), lovastatin, simvastatin,        drosperinone, Revatio<sup>\u00ae<\/sup> (sildenafil) or Adcirca<sup>\u00ae <\/sup>(tadalafil)        (when used for the treatment of pulmonary arterial hypertension),        pimozide, triazolam, and midazolam (orally administered).     <\/p>\n<p>       Anemia has been reported with peginterferon alfa and ribavirin therapy.        The addition of VICTRELIS to peginterferon alfa and ribavirin is        associated with an additional decrease in hemoglobin concentrations. The        addition of VICTRELIS may result in a worsening of neutropenia        associated with peginterferon alfa and ribavirin alone. Complete blood        counts should be obtained pretreatment, and at treatment weeks 4, 8 and        12, and should be monitored closely at other time points, as clinically        appropriate. If a patient has a serious adverse reaction potentially        related to peginterferon alfa and ribavirin therapy, the peginterferon        alfa and\/or ribavirin dose should be reduced or discontinued. VICTRELIS        must not be administered in the absence of peginterferon alfa and        ribavirin.     <\/p>\n<p>       The most commonly reported adverse reactions (greater than 35 percent)        in clinical trials in adult patients receiving the combination of        VICTRELIS with peginterferon alfa-2b and ribavirin were fatigue, anemia,        nausea, headache and dysgeusia. Of these commonly reported adverse        reactions, fatigue, anemia, nausea, and dysgeusia occurred at rates        greater than or equal to 5 percent above the rates for peginterferon        alfa and ribavirin alone in either clinical study. The incidence of        these adverse reactions in previously untreated patients who received        VICTRELIS combination therapy compared with peginterferon and ribavirin        alone were: fatigue (58 vs. 59 percent), anemia (50 vs. 30 percent),        nausea (46 vs. 42 percent), dysgeusia (35 vs. 16 percent), respectively.        The incidence of these adverse reactions in previously treated patients        who received VICTRELIS combination therapy compared with peginterferon        and ribavirin alone were: fatigue (55 vs. 50 percent), anemia (45 vs. 20        percent), nausea (43 vs. 38 percent), dysgeusia (44 vs. 11 percent),        respectively.     <\/p>\n<p>       VICTRELIS is a strong inhibitor of CYP3A4\/5 and is partly metabolized by        CYP3A4\/5. The potential for drug-drug interactions must be considered        prior to and during therapy.     <\/p>\n<p>       Please see U.S. prescribing information at: <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&amp;esheet=6799802&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&amp;index=1&amp;md5=24954d6fe3a4f448effca86503b742a6\">http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/a>.     <\/p>\n<p>       <b>Merck&#8217;s global commitment to advancing hepatitis therapy<\/b>     <\/p>\n<p>       Merck is committed to building on its strong legacy in the field of        viral hepatitis by continuing to discover, develop and deliver vaccines        and medicines to help prevent and treat viral hepatitis. In hepatitis C,        company researchers developed the first approved therapy for chronic HCV        in 1991 and the first combination therapy in 1998. In addition to        ongoing studies with VICTRELIS, extensive research efforts are underway        to develop additional innovative oral therapies for viral hepatitis        treatment.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6799802&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=261301570aa0977f6f289bf9bb3b3aaa\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the United States and internationally and the exposure to        litigation and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6799802&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=4737d492757635d8b78534b0d4cf5902\">www.sec.gov<\/a>).     <\/p>\n<p>       <b>Please see Prescribing Information for VICTRELIS at <\/b><a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&amp;esheet=6799802&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&amp;index=4&amp;md5=8dde49dc30e295a8748c0f302903bcf1\"><b>http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/b><\/a><b>        and Medication Guide for VICTRELIS at <\/b><a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&amp;esheet=6799802&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&amp;index=5&amp;md5=4d0686f429b28767c9e4bdd1c5f0fa82\"><b>http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_mg.pdf<\/b><\/a><b>.<\/b>     <\/p>\n<p>       <b>____________________ <\/b><br \/><sup>1<\/sup> SVR, the protocol        specified primary efficacy endpoint of the pivotal studies, is defined        as achievement of undetectable HCV-RNA at 24 weeks after the end of        treatment in all randomized patients treated with any study medication.        Per protocol, if a patient did not have a 24-week post-treatment        assessment, the patient\u2019s 12-week post-treatment assessment was utilized.     <\/p>\n<p>       <b>VICTRELIS<\/b><sup><b>\u2122<\/b><\/sup><b> is a trademark of Schering Corp.,        a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, N.J., USA.<\/b>     <\/p>\n<p>       <b>Revatio<\/b><sup><b>\u00ae<\/b><\/sup><b> and Adcirca<\/b><sup><b>\u00ae<\/b><\/sup><b>        are trademarks of their respective owners and are not trademarks of        Merck &amp; Co., Inc., Whitehouse Station, N.J., USA.<\/b>     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Investors:<br \/>Carol        Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), through the companies&#8217; respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS\u2122 (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg\/riba). &#8220;Reaching physicians with important information about the use of VICTRELIS in combination with peg\/riba is essential as we enter this new era in the field of chronic hepatitis C,&#8221; said Adam H. Schechter, executive vice president and president, Global Human Health, Merck. &#8220;We&#8217;re pleased to work with Roche to help physicians help patients with chronic hepatitis C around the world.&#8221; Under the terms of the agreement, Roche and Merck will work together in global markets, including Europe, Asia and Latin America, to educate physicians and patients about hepatitis C virus (HCV). The<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742107","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), through the companies&#039; respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS\u2122 (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg\/riba). &quot;Reaching physicians with important information about the use of VICTRELIS in combination with peg\/riba is essential as we enter this new era in the field of chronic hepatitis C,&quot; said Adam H. Schechter, executive vice president and president, Global Human Health, Merck. &quot;We&#039;re pleased to work with Roche to help physicians help patients with chronic hepatitis C around the world.&quot; Under the terms of the agreement, Roche and Merck will work together in global markets, including Europe, Asia and Latin America, to educate physicians and patients about hepatitis C virus (HCV). The\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\\\/\",\"name\":\"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-07-20T06:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY), through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS\u2122 (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg\/riba). \"Reaching physicians with important information about the use of VICTRELIS in combination with peg\/riba is essential as we enter this new era in the field of chronic hepatitis C,\" said Adam H. Schechter, executive vice president and president, Global Human Health, Merck. \"We're pleased to work with Roche to help physicians help patients with chronic hepatitis C around the world.\" Under the terms of the agreement, Roche and Merck will work together in global markets, including Europe, Asia and Latin America, to educate physicians and patients about hepatitis C virus (HCV). The","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:17+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/","name":"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-07-20T06:00:00+00:00","dateModified":"2026-08-10T17:01:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Roche Expand Agreement in Fight Against Chronic Hepatitis C"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7180045f-ef48-403b-a3e9-b4856b5c3066","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742107","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742107\/revisions"}],"predecessor-version":[{"id":3679243,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742107\/revisions\/3679243"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742107"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742107"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}